Trial Profile

A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Three-arm Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 01 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tabirafusp tedromer (Primary) ; Tarcocimab tedromer (Primary) ; Aflibercept
Indications Wet age-related macular degeneration
Focus Therapeutic Use
Acronyms DAYBREAK
Sponsors Kodiak Sciences

31 Mar 2026 According to Kodiak Sciences media release, Topline data is expected in September 2026.
26 Mar 2026 According to Kodiak Sciences media release, company anticipate a potential BLA submission for KSI-501 in wet AMD after the DAYBREAK study primary endpoint readout (expected 3Q2026).
13 Nov 2025 According to Kodiak Sciences media release, topline data expected in 3Q 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com